Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H22F3N5O |
Molecular Weight | 405.4168 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC(CNC2=NN3C(C=C2)=NC=C3C4=CC(OC(F)(F)F)=CC=C4)CC1
InChI
InChIKey=MHXGEROHKGDZGO-UHFFFAOYSA-N
InChI=1S/C20H22F3N5O/c1-27-9-7-14(8-10-27)12-24-18-5-6-19-25-13-17(28(19)26-18)15-3-2-4-16(11-15)29-20(21,22)23/h2-6,11,13-14H,7-10,12H2,1H3,(H,24,26)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19734450Curator's Comment: description was created based on several sources, including
http://astx.com/wp-content/uploads/2016/11/SUPG_News_2010_11_10_General_Releases.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19734450
Curator's Comment: description was created based on several sources, including
http://astx.com/wp-content/uploads/2016/11/SUPG_News_2010_11_10_General_Releases.pdf
SGI-1776 is a PIM-kinase inhibitor, developed by SuperGen Inc. SGI-1176 was tested in clinical trials against relapsed/refractory leukemias, prostate cancer and Non Hodgkin's Lymphoma, but the dose limiting toxicity of cardiac QTc prolongation was identified and clinical development of SGI-1776 was terminated.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19734450
Curator's Comment: SuperGen Inc. was merged with Astex in 2011 http://www.fiercebiotech.com/biotech/supergen-and-astex-therapeutics-enter-definitive-merger-agreement-creating-a-financially
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2147 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19734450 |
7.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01239108
In clinical trial SGI-1776 was administered orally at escalating dose levels ranging from 350 to 1600 mg/day. Clinical trial was prematurely terminated due to unacceptable toxicity of SGI-1776.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19734450
CLL cells were treated with DMSO alone or with 0.3, 1, 3, or 10 μmol/L SGI-1776 for 24 hours. Cells (10^6) were washed, resuspended in 100 μL of annexin binding buffer, and mixed with 5 μL of annexin–fluorescein isothiocyanate (FITC) solution and 5 μL of propidium iodide solution with 2.5 μg/mL DNase-free RNase A (Roche). At least 10 000 cells were measured per sample by the use of a Becton Dickinson FACSCalibur flow cytometer. Caspase inhibitor N-benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethylketone (ZVAD) was obtained from Alexis Biochemicals, and cells were treated with DMSO alone or 25 μmol/L ZVAD with or without 10 μmol/L SGI-1776 treatment for 24, 48, and 72 hours and then analyzed by flow cytometry. In vitro incubation of primary CLL cells (n = 7), with 1, 3, and 10 μmol/L SGI-1776 for 24 hours resulted in an average increase in apoptosis of 10%, 22%, and 38%, respectively, compared with untreated cells.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C82404
Created by
admin on Fri Dec 15 17:16:41 GMT 2023 , Edited by admin on Fri Dec 15 17:16:41 GMT 2023
|
PRIMARY | |||
|
1025065-69-3
Created by
admin on Fri Dec 15 17:16:41 GMT 2023 , Edited by admin on Fri Dec 15 17:16:41 GMT 2023
|
PRIMARY | |||
|
DTXSID10647329
Created by
admin on Fri Dec 15 17:16:41 GMT 2023 , Edited by admin on Fri Dec 15 17:16:41 GMT 2023
|
PRIMARY | |||
|
DB12494
Created by
admin on Fri Dec 15 17:16:41 GMT 2023 , Edited by admin on Fri Dec 15 17:16:41 GMT 2023
|
PRIMARY | |||
|
24795070
Created by
admin on Fri Dec 15 17:16:41 GMT 2023 , Edited by admin on Fri Dec 15 17:16:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL1952329
Created by
admin on Fri Dec 15 17:16:41 GMT 2023 , Edited by admin on Fri Dec 15 17:16:41 GMT 2023
|
PRIMARY | |||
|
72AUA0603W
Created by
admin on Fri Dec 15 17:16:41 GMT 2023 , Edited by admin on Fri Dec 15 17:16:41 GMT 2023
|
PRIMARY |
ACTIVE MOIETY